LNTH240719C55000
- 27.80
- 0.000.00%
Lantheus Newsroom
Mizuho Securities Maintains Lantheus(LNTH.US) With Buy Rating, Raises Target Price to $165
Mizuho Securities analyst Anthony Petrone maintains $Lantheus(LNTH.US)$ with a buy rating, and adjusts the target price from $100 to $165.According to TipRanks data, the analyst has a success rate
Express News | Lantheus Holdings Inc : Mizuho Raises Target Price to $165 From $100
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Conagra Brands, Inc. (NYSE:CAG) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted EPS guidance below
Top Midday Gainers
Truist Securities raised its price target for Lantheus Holdings (LNTH) to $141 from $96 while maintaining its buy rating.Lantheus shares jumped 16% amid heavy trading Thursday after Medicare
Lantheus Holdings Shares Are Trading Higher After Leerink Partners Maintained an Outperform Rating on the Stock and Raised Its Price Target From $106 to $127. Also, Truist Securities Maintained a Buy Rating on the Stock and Raised Its Price Target...
Lantheus Holdings Shares Are Trading Higher After Leerink Partners Maintained an Outperform Rating on the Stock and Raised Its Price Target From $106 to $127. Also, Truist Securities Maintained a
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday.Shares of Methode Electronics, Inc. (NYSE:MEI) rose sharply during Thursday's session after the company
A Quick Look at Today's Ratings for Lantheus(LNTH.US), With a Forecast Between $127 to $141
On Jul 11, major Wall Street analysts update their ratings for $Lantheus(LNTH.US)$, with price targets ranging from $127 to $141.Truist Financial analyst Richard Newitter maintains with a buy rating,
Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Morgan
Lantheus Holdings Is Maintained at Outperform by Leerink Partners
Lantheus Holdings Is Maintained at Outperform by Leerink
Lantheus Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 19.7% Leerink Partners $106 → $127 Maintains Outperform 05/03/2024 -9.52% Truist Securities $82
Express News | Lantheus Holdings Inc : Truist Securities Raises Target Price to $141.00 From $96.00
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Express News | Lantheus Holdings Inc : Leerink Partners Raises Target Price to $127 From $106
Truist Securities Adjusts Price Target on Lantheus Holdings to $141 From $96, Maintains Buy Rating
Lantheus Holdings (LNTH) has an average buy rating and a price target range of $100 to $150, according to analysts polled by Capital IQ.Price: 105.84, Change: -0.34, Percent Change: -0.32
Express News | Lantheus Holdings Inc : Truist Securities Raises Target Price to $141 From $96
Top Gap Ups and Downs on Wednesday: MA, INTU, HDB and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
New Reimbursement Rules For Diagnostic Radiopharmaceuticals Is 'Undoubtedly' Positive for Lantheus: Analyst
A recent announcement from Centers for Medicare & Medicaid Services (CMS) is "undoubtedly materially positive" for Lantheus Holdings (NASDAQ:LNTH) shares, an analyst noted.
Lantheus Buy Rating Affirmed Amid Favorable CMS Changes and Strong Market Position
Sector Update: Health Care Stocks Advance in Afternoon Trading
Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.6% and the Health Care Select Sector SPDR Fund (XLV) up 0.7%.The iShares Biotechnology ETF (IBB) climbed 1.1%.In
Sector Update: Health Care
Health care stocks rose Wednesday afternoon with the NYSE Health Care Index adding 0.7% and the Health Care Select Sector SPDR Fund (XLV) up 0.6%.The iShares Biotechnology ETF (IBB) rose 1%.In